AU2017303333B2 - Sustained release composition comprising micronized tolcapone - Google Patents

Sustained release composition comprising micronized tolcapone Download PDF

Info

Publication number
AU2017303333B2
AU2017303333B2 AU2017303333A AU2017303333A AU2017303333B2 AU 2017303333 B2 AU2017303333 B2 AU 2017303333B2 AU 2017303333 A AU2017303333 A AU 2017303333A AU 2017303333 A AU2017303333 A AU 2017303333A AU 2017303333 B2 AU2017303333 B2 AU 2017303333B2
Authority
AU
Australia
Prior art keywords
tolcapone
tablet
cellulose
weight
tablet according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017303333A
Other languages
English (en)
Other versions
AU2017303333A1 (en
Inventor
Santiago ESTEVA GRAS
Oscar HUERTAS GAMBÍN
Raúl INSA BORONAT
Anna Nardi Ricart
Gal.La Pericot Mohr
Núria REIG BOLAÑO
Josep María SUÑÉ NEGRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Som Innovation Biotech SA
Original Assignee
Som Innovation Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Som Innovation Biotech SA filed Critical Som Innovation Biotech SA
Publication of AU2017303333A1 publication Critical patent/AU2017303333A1/en
Application granted granted Critical
Publication of AU2017303333B2 publication Critical patent/AU2017303333B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017303333A 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone Active AU2017303333B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382372.7 2016-07-29
EP16382372.7A EP3275433A1 (en) 2016-07-29 2016-07-29 Sustained release composition comprising micronized tolcapone
PCT/EP2017/069168 WO2018019997A1 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Publications (2)

Publication Number Publication Date
AU2017303333A1 AU2017303333A1 (en) 2019-03-14
AU2017303333B2 true AU2017303333B2 (en) 2023-03-30

Family

ID=56571284

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017303333A Active AU2017303333B2 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Country Status (12)

Country Link
US (2) US11883538B2 (OSRAM)
EP (2) EP3275433A1 (OSRAM)
JP (1) JP7047236B2 (OSRAM)
KR (1) KR102484678B1 (OSRAM)
CN (1) CN109789100A (OSRAM)
AU (1) AU2017303333B2 (OSRAM)
DK (1) DK3490535T3 (OSRAM)
ES (1) ES2891355T3 (OSRAM)
MX (1) MX391116B (OSRAM)
PT (1) PT3490535T (OSRAM)
RU (1) RU2750670C2 (OSRAM)
WO (1) WO2018019997A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025536853A (ja) * 2022-10-10 2025-11-07 コリノ セラピューティクス，インク． 放出調節トルカポン処方剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112053A1 (en) * 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
US20140296188A1 (en) * 2011-10-24 2014-10-02 Som Innovation Biotech, S.L. New therapy for transthyretin-associated amyloidosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DE69733752T2 (de) 1996-05-20 2006-06-01 G.D. Searle Llc, Chicago Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz
AU3705799A (en) 1998-04-09 1999-11-01 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US9492388B2 (en) * 2002-12-20 2016-11-15 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
CA2611114C (en) * 2005-06-08 2014-09-23 Orion Corporation An entacapone-containing oral dosage form
PL2640358T3 (pl) * 2010-11-15 2018-06-29 Neuroderm Ltd Ciągłe podawanie l-dopy, inhibitorów dopa-dekarboksylazy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji
CN103415513B (zh) 2011-03-14 2016-01-20 勃林格殷格翰国际有限公司 白三烯产物的苯并二氧杂环己烷抑制剂
US20130195973A1 (en) * 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
BR112015022390A8 (pt) * 2013-03-13 2019-11-26 Neuroderm Ltd uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson
KR102457026B1 (ko) * 2013-11-05 2022-10-21 신애질 코포레이션 입을 통한 연속적 약물 전달
WO2016036308A1 (en) * 2014-09-04 2016-03-10 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112053A1 (en) * 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
US20140296188A1 (en) * 2011-10-24 2014-10-02 Som Innovation Biotech, S.L. New therapy for transthyretin-associated amyloidosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Rote Liste 2012", 2 January 2012, article UNKNOWN: "Tasmar 100mg", XP055331811 *

Also Published As

Publication number Publication date
RU2750670C2 (ru) 2021-06-30
MX2019001190A (es) 2019-09-06
MX391116B (es) 2025-03-21
BR112019001826A2 (pt) 2019-05-07
KR102484678B1 (ko) 2023-01-03
WO2018019997A1 (en) 2018-02-01
PT3490535T (pt) 2021-09-30
RU2019103647A3 (OSRAM) 2020-10-12
EP3490535A1 (en) 2019-06-05
AU2017303333A1 (en) 2019-03-14
EP3490535B1 (en) 2021-07-14
RU2019103647A (ru) 2020-08-28
JP2019523305A (ja) 2019-08-22
US12220487B2 (en) 2025-02-11
ES2891355T3 (es) 2022-01-27
CN109789100A (zh) 2019-05-21
US20190167596A1 (en) 2019-06-06
US20240216282A1 (en) 2024-07-04
KR20190034563A (ko) 2019-04-02
JP7047236B2 (ja) 2022-04-05
CA3032211A1 (en) 2018-02-01
US11883538B2 (en) 2024-01-30
EP3275433A1 (en) 2018-01-31
DK3490535T3 (da) 2021-10-04

Similar Documents

Publication Publication Date Title
JP4757872B2 (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
CA2956527C (en) Directly compressible polyvinyl alcohols
JP6706245B2 (ja) 微結晶性セルロースを含む直接圧縮可能な組成物
AU2014225449B2 (en) Stabilization of moisture-sensitive drugs
US20250249015A1 (en) Novel rivaroxaban formulation
US12220487B2 (en) Sustained release compositions comprising micronized tolcapone
CA3032211C (en) Sustained release composition comprising micronized tolcapone
JP6002869B1 (ja) ジエノゲスト含有錠剤
JP6918393B1 (ja) 漢方エキス又は植物性生薬エキスを含む固形製剤及びその製造方法、並びに固形製剤の崩壊性を向上させる方法
BR112019001826B1 (pt) Composição de liberação prolongada compreendendo tolcapone micronizada
JPH02282322A (ja) 有効物質の浸食制御による放出システムおよびその製造方法
JP2017075138A (ja) ジエノゲスト含有錠剤
HK40008562A (en) Sustained release composition comprising micronized tolcapone
JP2676305B2 (ja) シタラビンオクホスファート硬カプセル剤
WO2021148362A1 (en) Directly compressible polymer combinations for matrix tablets with extended drug release
WO2017064815A1 (ja) 低用量薬物を含有する口腔内崩壊錠
GB2491205A (en) Composition comprising bosentan and diluents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)